【INTRODUCTION】Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer. Since TNBC exhibits a significantly lower 5-year survival rate than other subtypes, development of novel therapeutic strategies for TNBC is urgently needed. Tumor suppressor gene Cylindromatosis (CYLD) is associated with acquisition of malignant traits in various malignant tumors as a negative regulator for intracellular signals, such as nuclear factor-κB (NF-κB) signaling. The aim of this study was to clarify the clinical and biological significance of reduced CYLD expression in TNBC and to explore novel pharmacotherapy CYLD-negative poor-prognosis TNBC patients.

Triple-negative breast cancer

10.1254/jpssuppl.97.0_3-b-o14-4

Cite

Citations (0)

Biological significance of CYLD downregulation in Triple negative breast cancer.

Proceedings for Annual Meeting of The Japanese Pharmacological Society (2021)

Akari Kuwano Chika Hirai Naoki Suenaga Ayumi Kanemaru Hitomi Arakaki

Purpose: Tumor suppressor cylindromatosis (CYLD) regulates various cell signaling pathways, such as nuclear factor-kB (NF-kB), as its aberrant activation contributes to malignant progression. Although we showed that loss of CYLD expression in triple breast cancer (TNBC), the most aggressive breast cancer type, contributed to poor prognosis, the roles of CYLD expression in TNBC remain unknown. In this study, we evaluated the biological significance of CYLD expression in the malignant progression of TNBC in terms of cell migration and drug resistance.

Triple-negative breast cancer

10.1254/jpssuppl.94.0_1-y-e3-2

Cite

Citations (0)